Fred Hutchinson researchers find that a new drug shows promise in treating indolent non-Hodgkin lymphomas
A new drug, idelalisib, showed promise in a phase 2 study for treating patients with indolent non-Hodgkin lymphoma.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.